Increased proliferation, defective apoptosis, and cytokine dysregulation of T lymphocytes are thought to be important for the pathogenesis of inflammatory bowel disease. Since these phenomena can be corrected by aCD2 mAb, we asked whether CD2 directed immunotherapy safely prevents and/or ameliorates adoptive transfer colitis. Colitis was induced by transfer of CD4 þ T cell blasts to syngenic RAG1 À/À mice or CD45RB high CD4 þ T cells to SCID mice. The aCD2 mAb 12-15 or rat IgG was given, starting either initially or upon first signs of colitis. Disease activity was assessed by clinical monitoring, microscopic scoring, hemoccult, endoscopy, and blood count analysis. Cytokine production of stimulated LPL was measured by ELISA and cell proliferation by [ 3 H]-thymidine incorporation. Parasite control was analyzed in a murine model of infection with Toxoplasma gondii. The aCD2 mAb significantly increased mean survival time when starting at transfer of blasts (survival 435 days: aCD2 69% vs 0% of controls, Po0.001). In the SCID colitis model hematochezia and macroscopic colitis were delayed. When used in established T-cell blast colitis, the benefit was less pronounced, even in combination with dexamethasone (mean survival7s.e.m.: aCD2 þ dexa: 13.572.9 vs dexa þ IgG: 6.371.0, Po0.05). In the preventive experiment the aCD2 mAb markedly reduced IL-2 secretion and T-cell proliferation. The immune response towards Toxoplasma gondii was not impaired. These studies show for the first time that CD2 directed immunotherapy can attenuate or delay adoptive transfer colitis and ameliorate established colitis. Most likely inhibition of IL-2 secretion and T-cell proliferation are responsible for these effects. Still, immune defence towards T. gondii is maintained.
Inflammatory bowel disease (IBD) is characterized by mononuclear cell infiltration of affected bowel segments, consisting primarily of macrophages and T helper (Th) cells. The number of T helper cells can increase within the intestine by enhanced T-cell proliferation, reduced T-cell apoptosis, and increased adhesion. [1] [2] [3] [4] [5] Proinflammatory cytokines are strongly involved in these processes showing a Th 1 dominance in most animal models. [6] [7] [8] CD2, a widely distributed glycoprotein, plays a pivotal role in the immunological synapse adapting T cells with antigen presenting cells. 9, 10 Signals via CD2 are important for both antigen-dependent as well as antigen-independent T-cell activation. 11, 12 For mucosal immunology, CD2 plays an even more important role, since lamina propria T cells (LPL-T) proliferate via CD2 but much less via the CD3/T-cell receptor complex, both in vitro and in vivo. 13, 14 In addition, cytokine secretion by LPL-T as well as LPL-T-cell apoptosis is mediated via CD2. [15] [16] [17] Also, CD2 seems to be involved in the induction of regulatory T cells. 18, 19 MAb directed at CD2 inhibit T-cell proliferation, 20, 21 induce LPL-T apoptosis, 16 inhibit Th 1 cytokine production, and induce Th 2 and Th 3 cytokines. [22] [23] [24] Accordingly, aCD2 mAb were used successfully in both transplantation models, [25] [26] [27] [28] arthritis and multiple sclerosis animal models. [29] [30] [31] Clinical studies suggest that CD2 is a promising target in psoriasis. 32 Therefore, we asked whether aCD2 mAb are effective in a colitis animal model, that is, adoptive transfer colitis. Specific immunotherapies (eg aTNF-a mAb) have been associated with impaired host defence. 33 To investigate whether aCD2 mAb treatment impairs host defences against intracellular microorganisms, we analyzed numbers of parasites following oral infection of mice with Toxoplasma gondii. Following peroral infection of C57BL/6 mice with T. gondii, parasites replicate in the small intestines and induce a Th1-mediated small-intestinal immunopathology. 34 Here, we demonstrate that aCD2 mAb treatment partially prevents transfer colitis and slows down the inflammatory course in established disease. At the same time, treatment appeared to be safe, since the host defence against T. gondii was not impaired.
Materials and methods

Animals
Donor mice (C57BL/6) and RAG1
À/À mice were obtained from I. Fö rster, Munich, Germany, and were bred under specific pathogen-free (SPF) conditions at the Research Institute for Experimental Medicine (FEM), Berlin, Germany, or at the animal care facility of the University Hospital of Saarland at Homburg, Germany. BALB/c donor mice and C.B-17 SCID mice were obtained from Harlan, USA. Mice were kept in polycarbonate cages and had free access to sterile standard chow and water. All animal experiments were approved by the local animal protection committee.
Induction of Transfer Colitis
Two different models of transfer colitis were used: (1) Induction of colitis by CD4 þ T cell blasts ('T cell blast transfer colitis') and (2) Induction of colitis by transfer of CD45RB high T cells ('classical CD45RB high SCID transfer colitis'). For transfer of CD4 þ blasts spleens were removed from donor mice (C57BL/6) and teased into single-cell suspensions in phosphate-buffered saline (PBS). Erythrocytes were removed by hypotonic lysis. Cells were washed and stimulated with 5 mg/ml ConA for 3 days. CD4
þ T blasts were generated by CD8-mediated complement lysis using the aCD8 Ab (53.6-7) and low-toxicity rabbit complement (Biozol, Eching, Germany) followed by positive selection with aCD4-coupled magnetic beads on LS MACS separation columns (Miltenyi Biotec, Germany). Eluted CD4 þ T cells were washed and resuspended in sterile PBS, and 3 Â 10 5 purified CD4 
Monoclonal Antibodies
The following monoclonal antibodies (mAbs) were used in vivo: 12-15 (rat IgG1, kindly provided by P. Altevogt, Heidelberg, Germany), directed at the mouse CD2 molecule, and control rat IgG (Sigma, Germany). The following mAbs were used in vitro: 145-2C11 (hamster IgG1, ATCC), directed at murine CD3e; 37.51 (hamster IgG2), directed at murine CD28 (BD Biosciences, Germany); and 53.6-7, directed at murine CD8 (ATCC). The mAb 12-15, 53.6-7, and 145-2C11 were purified from supernatants of the hybridoma cell lines by affinity chromatography employing Protein G Sepharose (Pharmacia, Freiburg, Germany).
mAb Treatment
Treatment with the aCD2 mAb 12-15 was performed in a blinded fashion in four treatment blocks. In transplantation experiments 100 mg of 12-15 per week was found to be as effective as higher concentrations. 25 Therefore, mice were loaded with 400 mg followed by 200 mg per week. The treatment blocks consisted of at least four separate blocks each:
(i) Prevention of transfer colitis induced by transfer of CD4 þ T cell blasts: 400 mg purified 12-15 (n ¼ 16) or rat IgG (n ¼ 13) was given i.p. just prior to colitis induction, followed by 200 mg weekly thereafter. This treatment block was performed at two different sites (Homburg and Berlin, Germany).
(ii) Treatment of established transfer colitis (induced by transfer of CD4 þ T-cell blasts) in combination with dexamethasone (1 mg/kg body weight): antibody treatment was started at the beginning of signs of illness (diarrhea or loss of weight 4 5%) with 400 mg aCD2 (n ¼ 8) or rat-control IgG (n ¼ 8) in combination with 1 mg dexamethasone per kg, that is, 15-25 mg per mouse, and was continued with 200 mg antibody combined with dexamethasone (1 mg/kg) on days 1, 4, and subsequently weekly.
(iii) Treatment of established transfer colitis induced by transfer of CD4 þ T cell blasts (without dexamethasone treatment): treatment began upon first signs of disease (diarrhea or weight loss 45%) with 400 mg 12-15 (n ¼ 9) or controlantibody (n ¼ 9), followed by weekly administration of 200 mg aCD2 or rat IgG. Mice were monitored for weight loss, rectal prolapse, and diarrhea. Mice that received CD45RB high T cells were monitored weekly for hematochezia by hemoccult test from day 21 after transfer. Additionally, 6 weeks after transfer the grade of CD45RB high transfer colitis was examined by endoscopy as previously described. 35 Blinded videofilms of mouse endoscopy were scored by an experienced endoscopist using a scoring system from 0 to 4 as follows: 0 ¼ normal mucosal vascularity and lumen, 1 ¼ diminished vascularity, 2 ¼ erythema7edema, 3 ¼ no vascularity and small ulcers, 4 ¼ severe ulceration7stenosis. All mice were killed by cervical dislocation for macroscopical, histological, and cytological examinations when they exhibited one or two of the following signs: weight loss 420%, obvious signs of pain, lethargy.
Blood samples were taken from the heart for blood count analysis using an automatic cytometer (Beckmann Coulter, Germany) and two differential blood smears were prepared. At autopsy spleen, mesenteric lymph nodes (mLN), cecum, and the large intestine were excised. Samples of the cecum and colon were obtained for paraffin sections. The remaining tissues of the large intestine were used for isolation of lamina propria lymphocytes (LPLs).
Depletions Studies
In order to exclude potential effects exerted by the aCD2 mAb 12-15, we transferred 4 Â 10 6 CFSElabeled CD4
þ ConA-blasts to RAG1 À/À mice and treated them with either 400 mg 12-15, rat IgG, or GK1.5 (CD4 þ depleting antibody) (n ¼ 3 for each group). On day 1, we took blood samples and on day 3 recipients were killed. Lymphocytes of peripheral blood cells, spleen, mLN, and lamina propria were isolated as described before. The isolated cells were stained for CD103 (R-PE-conjugated; BD Pharmingen, Heidelberg, Germany) and CD25 (PerCP-CY5.5-conjugated; BD Pharmingen), and CFSE-labeled cells were analyzed by flow cytometry as described below.
CFSE-Labeling, Staining for Intracellular IL-10, and Flow Cytometry
For CFSE-labeling, CD4
þ ConA blasts (1 Â 10 7 /ml; prepared as described before) were incubated with 1 mM CFSE (10 min, room temperature), washed twice, and transferred to RAG1 À/À mice. At 3 days after transfer, cells were isolated from RAG1 À/À recipients (as described above) and stained with saturating amounts of directly conjugated mAb (R-PE-conjugated CD103, Per-CP/anti-CD25-CY5.5-conjugated, BD Pharmingen, Heidelberg) for 10 min at 41C, washed, and analyzed on the fluorescenceactivated cell sorter (FACScan, Becton Dickinson, Heidelberg, Germany).
For intracellular staining of IL-10, isolated cells were stimulated (2 mg/ml ConA, 5 days) and restimulated (10 mg/ml PMA þ 1 mg/ml Ionomycin) for 6 h. BrefeldinA (5 mg/ml) was added 3 h before cells were harvested and fixed (2% paraformaldehyde, 10 min). Cells were permeabilized and stained in 0.5% saponin (Merck, Darmstadt) for 10 min at room temperature. Cytokine production was assessed by intracellular staining with FITC-conjugated IL-10 (BD Pharmingen, Heidelberg, Germany) and measured by flow cytometry.
Histological Examination and Microscopic Scoring
Tissue samples of the colon were fixed in 4% formalin and embedded in paraffin. Sections (5 mm) were stained with hematoxylin and eosin for histology. The degree of inflammation was blindly assessed by two investigators using a scoring system, which was modified for the original score as described by Neurath et al 36 from 0 to 4 (0, no signs of inflammation; 1, low level of leukocyte infiltration; 2, moderate level of leukocyte infiltration; 3, high level of leukocyte infiltration, high vascular density, and thickening of bowel wall; 4, transmural infiltration, loss of goblet cells, high vascular density, strong bowel wall thickening, ulcerations, and crypt abscesses).
Isolation of Spleen Cells, mLN Cells, and LPL
Single cell suspensions were prepared as described above using a 70 mm mesh cellstrainer (BD Biosciences, Germany). For isolation of lamina propria lymphocytes (LPL), the colon (with rectum) was opened longitudinally and cut into 0.5 cm pieces. The fragments were shaken at 371C in HBSS (Ca 2 þ / Mg 2 þ -free) containing 1 mM DTT and 2.5 mM EDTA for 45 min with two changes of media. The pellets were resuspended in collagenase medium and shaken for 90 min at 371C. After digestion of tissue, the suspensions were passed through a 70 mm mesh cellstrainer and centrifuged on a Percoll density gradient (100/40%). LPL were collected from the interphase and resuspended in complete medium (RPMI 1640 medium containing 10% fetal calf serum (FCS), 100 U/mL penicillin/streptomycin, 3 mM glutamine, and 50 mM b-mercaptoethanol). The cell viability was always greater than 90% as determined by trypan blue dye exclusion.
Cytokine Assay
Isolated spleen cells, mLN cells, and LPL (1 Â 10 6 cells/ml in 24-well plates (NUNC, Germany)) were aCD2 antibody treatment attenuates colitis NN Pawlowski et al stimulated with coated 145-2C11 (10 mg/ml) and soluble aCD28 mAb 37.51 (1 mg/ml). Supernatants were taken after 48 h and examined for cytokine secretion (IL-2, IL-4, IL-6, IL-10, TNF-a, and IFN-g) by sandwich ELISA. Antibodies (purified and biotinylated) as well as recombinant protein standards for IL-4, IL-10, and IFN-g (R&D Systems, Germany) and IL-2, IL-6, and TNF-a (BD Biosciences, Germany) were used according to the manufacturer's instructions. 
Proliferation of Spleen Cells, mLNs, and LPL
Infection with T. gondii and aCD2 mAb Treatment during Toxoplasmosis
Female C57BL/6 mice were infected with 100 cysts of the ME49 strain of T. gondii by gavage as previously described. 34 Overall, 23 mice were blindly treated with either rat IgG (control group, n ¼ 8) or the aCD2 mAb 12-15 (n ¼ 15) with a loading dose of 200 mg on the day of infection followed by daily doses of 100 mg until day 7. In all, 12 mice were killed on day 12 of infection (four control mice and eight aCD2 mAb-treated mice). The number of parasites per cm ileum was determined as previously described. 34 For the remaining 11 mice (four control and seven aCD2 mAb-treated mice), the survival was monitored.
Statistical Analysis
Statistical analysis was carried out using SPSS for Windows. Survival was analyzed using KaplanMeier analysis. For other comparisons, the MannWhitney U-test was used. Values were expressed as mean (95% confidence intervals) and standard error of mean (s.e.m.). A P value of less than 0.05 was considered significant.
Results
The Figure 2 ). When using the classical SCID transfer colitis model (CD45RB high CD4 þ T cells on SCID mice; n ¼ 10 in each group as above) neither aCD2 mAbtreated nor control mice died within 56 days after colitis induction (data not shown). However, only 10% of the aCD2 mAb treated mice had a positive hemoccult test by day 28 as compared to 80% in the control group (Figure 3) . Similarly, a significant difference between both groups was found at blinded mouse endoscopy on day 42 ( Figure 4) . Still, all animals in the aCD2 mAb group eventually developed colitis as jugded by macroscopic and microscopic criteria at the end of the experiment (day 56). Only a trend towards improvement was observed with regard to the macroscopic score (aCD2: 1.570.15 vs controls: 1.970.22, Po0.1) and no significant difference with regard to the microscopic score (aCD2: 2.370.5 vs 2.870.4, P ¼ 0.3). Blood count analysis revealed no significant differences with regard to hemoglobin, red cell numbers, and platelet counts in both models (data not shown). However, the aCD2 mAb 12-15 prevented leukocytosis when compared to rat IgG treated control mice (aCD2: 2.9770.61/ml vs controls: 6.4570.92/ml , Po0.05) in the T cell blast model, but only a trend was found in the classical SCID transfer colitis model (aCD2: 6.271.6/ml vs controls: 8.5.71.4/ml). Differential blood counts revealed a significant reduction of lymphocytes in both models (T cell blast model: aCD2: 0.2370.03/ml vs 0.3970.033/ml, P ¼ 0.02; CD45RBhigh model: aCD2: 0.770.15/ml vs 2.570.44/ml, Po0.001) and a significant reduction of granulocytes only in the T cell blast transfer colitis model (aCD2: 2.7470.59/ml vs 6.3571.04/ml, P ¼ 0.03). When 4 Â 10 6 CFSElabeled CD4 þ T cell blasts were transferred into RAG1 À/À mice, aCD2 mAb treatment did not change
þ /CFSE þ cells neither after 24 nor 72 h in peripheral blood, or at 72 h in mLN, spleen, or LPL when compared to rat IgG treatment (data not shown).
aCD2 Antibody 12-15 Ameliorates Established Colitis
To test the effect of 12-15 in already established colitis we transferred CD4 þ T cell blasts into 18 RAG1 À/À mice. At the first sign of colitis (diarrhoea and/or weight loss) treatment was started. aCD2 antibody treatment (given on day 0 of established colitis at 400 mg followed by 200 mg weekly) prolonged the average survival after the start of treatment significantly (aCD2 (n ¼ 9): 8.671.4 days vs rat IgG (n ¼ 9): 5.8 7 0.7; Po0.05) ( Figure 5) .
In order to improve the clinical effect of aCD2 mAb treatment, we next asked whether pulse dexamethasone treatment had any additional effect on established colitis. Among 16 transferred RAG1 À/À mice, all animals developed colitis within 25 days. aCD2 mAb plus dexamethasone (1 mg/kg) (n ¼ 8) or dexamethasone plus rat IgG (control) (n ¼ 8) was applied at a mAb/rat IgG dose of 400 mg immediately after colitis was detected (day 0 of established colitis) followed by 200 mg on days 1, 4, and weekly thereafter. When mice with established colitis were treated with aCD2 plus dexamethasone they survived more than twice as long (13.572.9 days after initial signs of colitis) as compared with the control group receiving dexamethasone and rat IgG (6.371.0 days, Po0.05) (Figure 6 ). Importantly, dexamethasone did not affect mean survival time when compared to rat IgG alone (24.5 vs 26 days). À/À mouse after induction of transfer colitis either following aCD2 mAb (12-15) treatment (a) or rat IgG (b) treatment at weekly intervals starting at 400 mg followed by 200 mg is shown. While aCD2 mAb treatment ameliorates adoptive transfer colitis with a nearly normal histological appearance of the colon (a, Â 100), the colon of a rat IgG treated mouse (b, Â 100) shows colonic crypt hyperplasia, disorganization, inflammatory infiltrations, strong bowel wall thickening, reduction of goblet cells, as well as crypt abscesses. aCD2 mAb 12-15 alone or in combination with dexamethasone was not able to decrease clinical, histological or systemic (WBC, RBC, platelets) signs of transfer colitis when given for established colitis.
aCD2 mAb Treatment does not Impair Parasite Control Following Peroral T. gondii Infection
In order to assess potential nonspecific immunosuppression, the influence of aCD2 mAb treatment on infection with T. gondii was studied. Importantly, the number of parasites did not differ in the aCD2 mAb treated vs control group (mean7s.e.m. for aCD2 mice: 3347161 vs control group: 274769; P ¼ 0.7). Furthermore, a trend towards longer survival was found in this model of Th1-mediated immunopathology for aCD2 mAb treated as compared to control mice (P ¼ 0.1).
aCD2 mAb Decreases IL-2 Production in CD3/CD28 Stimulated Splenocytes and LPL
Since several studies have shown a Th 1 driven immunopathogenesis of transfer colitis, we asked whether aCD2 treatment influences cytokine production. LPL of aCD2 mAb treated animals had a significant reduction of IL-2 production upon stimulation with aCD3/aCD28 mAbs as compared to the control group (n ¼ 5 each; preventive experiment; Po0.001; Figure 7a ). This finding was confirmed both in splenocytes (Po0.001, Figure 7b , prevention) and mLN cells (Po0.05, Figure 6c , prevention). This was also true for the classical SCID transfer colitis model (data not shown). Treatment with aCD2 in combination with dexamethasone (n ¼ 8) led to a significant decrease in IL-2 production in LPL (Po0.05), and to a slight but nonsignificant decrease in splenocytes (Po0.1) and mLN cells (Po0.1). aCD2 alone was not able to decrease IL-2 production in LPL, spleen, or mLN cells in established colitis (data not shown).
No differences were found with regard to production of the cytokines IL-6, IL-10, IFN-g, and TNF-a in all three experiments using the T cell blast transfer model. In contrast, TNF-a levels in the classical SCID transfer colitis model significantly decreased in the supernatant of LPLs but not splenocytes or mLN. IL-4 was not increased in the aCD2 mAb treated groups as compared to the rat IgG treated control groups (data not shown). Importantly, no differences were seen when looking at intracellular IL-10 levels by flow cytometry (data not shown).
aCD2 Decreases Proliferation of CD3/CD28 Stimulated Cells
To test whether aCD2 could alter other T cell functions, proliferation of splenocytes, mLN cells, and LPL was investigated. Spleen and mLN cells from aCD2 mAb-treated animals had a significantly decreased proliferative response to CD3/CD28 stimulation in vitro (Figure 8a , splenocytes of preventively treated mice (Po0.01), Figure 8b , mLN cells of preventively treated mice (Po0.05)). Overall proliferation of LPL was too low for comparison (not shown).
aCD2 mAb in combination with dexamethasone also reduced the proliferative response when compared to dexamethasone plus control rat IgG; however, this difference was only significant in mLN cells, not in spleen cells (Figure 8a , established colitis: aCD2 þ dexa, splenocytes, Figure 8b , established colitis: aCD2 þ dexa, mLN cells (Po0.05)).
Mice treated with aCD2 mAb alone showed no decrease in proliferation of stimulated splenocytes, mLN cells, or LPL.
Discussion
In this study, we demonstrate for the first time the ability of an aCD2 mAb to delay the development of adoptive transfer colitis and to decrease the signs of inflammation in established transfer colitis. Most likely, this beneficial effect results from markedly À/À mice treated either with aCD2 mAb (12) (13) (14) (15) or control IgG starting at transfer (prevention). Established colitis was treated with aCD2 mAb (12) (13) (14) (15) or rat control IgG plus 1 mg/kg dexamethasone at days 0, 1, 4, 7, 14 after first signs of colitis. Cells were isolated from the colon of colitic mice and activated for two days with aCD3 and aCD28 mAb. IL-2 was measured by ELISA and is expressed as box plots. The level of significance is indicated (*Po0.05; ***Po0.001) and was determined by the Mann-Whitney U-test.
reduced IL-2 production and inhibition of T-lymphocyte proliferation, two characteristics of adoptive transfer colitis. Presumably, due to the severity of the model, this immunotherapy neither prevents colitis completely nor does it cure established disease. Still, aCD2 treatment effects are almost as good as previous reports on aTNF-a mAb treatment in CD45RB high transfer colitis, 37 a therapy that turned out to be effective in refractory Crohn's disease. 38 An important histological feature of inflammatory bowel disease is the strong mononuclear cell infiltrate consisting mainly of CD4 þ T lymphocytes. Increased proliferation, 1 defective apoptosis, 2, 3 increased adhesion, 39 and enhanced lymphokine production 1, 40 are generally thought to be responsible. In order to investigate these processes and to obtain an effective immunotherapy for IBD, animal models are a useful tool. The most widely used model is the adoptive transfer colitis having a Th 1 dominance, which exists with many variations mainly using either sorted CD45RB high T helper cells or alternatively T cell blasts. 41, 42 Enhanced adhesion as well as increased colonic T cell proliferation and apoptosis are additional features of this model. 43, 44 Therefore, adoptive transfer colitis serves as a useful model to investigate the role of T cells in IBD, particularly with regard to cytokine dysbalance (Th 1 dominance as in Crohn's disease), increased proliferation, and probably enhanced adhesion. In contrast to other IBD models the colitis induced by transfer of CD4 þ T cell blasts to SCID mice or RAG1
À/À mice results in highly reproducible severe colitis with 100% mortality within 35 days. Our results show that indeed mAb directed at the T cell antigen CD2 have a positive effect on survival and the degree of inflammation in transfer colitis. Additional experiments using the classical CD45RB high transfer colitis model revealed that the aCD2 mAb delays but does not prevent colitis development as seen with delayed hematochezia and reduced mucosal inflammation when using endoscopy on day 42.
Previous studies have shown that aCD2 mAbs can ameliorate chronic inflammatory diseases, that is, adjuvant arthritis, 29 or prolong transplantation survival in different species. [25] [26] [27] [28] So far, aCD2 mAb treatment has only been tested in one IBD animal model, that is, rat 2,4,6-trinitrobenzene sulphonic acid-induced colitis. 45 As this model turned out to be T cell independent, we were unable to find a beneficial effect by aCD2 mAb in this rat colitis model. In contrast, we now show that CD2-directed immunotherapy can partially prevent T cellmediated colitis and can attenuate already established colitis, particularly in combination with dexamethasone.
The most likely underlying mechanism of the aCD2 mAb treatment is its inhibitory effect on mLN/ splenocyte proliferation as well as reduced IL-2 production by LPL, mLN, and splenocytes, suggesting that IL-2 serves as an autocrine growth factor. This previously reported 46 and highly reproducible effect probably leads to a reduction of absolute lymphocyte numbers at the end of the experiments. Since mitogenic aCD2 mAb can strongly induce IL-2 production via the AP-1 signalling pathway, 47 inhibition of IL-2 production is probably due to the sterical blockade of the CD2 molecule. In addition, we were unable to find evidence of the induction of regulatory T cells as measured by flow À/À mice treated preventively with 12-15 or rat-control IgG, respectively, are shown. Established colitis was treated with aCD2 mAb 12-15 or rat IgG (initially 400 mg followed by 200 mg, days 0, 1, 4, 7, 14) in combination with 1 mg/kg dexamethasone once colitis was clinically overt. After in vitro stimulation with aCD3-coated plates and soluble aCD28, cells were cultured and proliferation was determined by [ 3 H]-thymidine uptake. The proliferative indices (counts of sample/baseline counts) are expressed as box plots. The level of significance is indicated (*Po0.05; **Po0.01) and was determined by the Mann-Whitney U-test.
cytometry of CD25 and CD103 expression of the transferred T cells. This again confirms previous reports that the aCD2 mAb 12-15 has no effect on CD25 expression. 48 Further, no effect was seen with regard to IL-10 secretion by splenocytes, mLN, or LPL upon CD3/CD28 stimulation. Therefore, it seems highly unlikely that this particular aCD2 mAb induces classical regulatory T cells. This seems to be important, because human studies suggest that regulatory T cells are induced via CD2. 18 Finally, in our hands this mAb did not induce Th 2 cytokines as reported by Chavin et al.
22
Apart from inhibition of proliferation 20, 21, 49 and a reduction of IL-2 production 50 aCD2 mAb have previously been shown to induce T cell apoptosis of LPL 16 and to block T cell adhesion leading to reduced tumor cytotoxicity. 51 In the past, we found that apoptosis induction via human CD2 usually only occurs when proliferation is induced at the same time (Hoffmann et al, submitted). Others were not able to find peripheral T cell depletion by this aCD2 mAb, 48 while we found a moderate reduction of lymphocytes probably due to less T cell proliferation rather than apoptosis induction.
Originally, CD2 was discovered via its role in in vitro and later in vivo tumor cytotoxicity. 20, 51 However, studies using CD2 deficient mice did not show an increased tumor incidence or general immunsuppression as demonstrated by normal cellular immune responses upon infection with lymphocytic choriomeningitis virus or Pneumocystis carinii.
52,53
Treatment of Crohn's disease patients and patients with rheumatoid arthritis with aTNF a mAb recently taught us that specific immunotherapies can not only potently suppress disease activity but also reactivate latent infections such as tuberculosis, sometimes with fatal consequences. 33 Previous studies have shown that Th 1 cells (ie secreting TNF-a, interferon g and NO) are required for parasite control in the murine model of oral infection with T. gondii. 34, 54 Importantly, the aCD2 mAb described here did not affect parasite control. Therefore, there is no evidence that the CD2-directed immunotherapy leads to significant immunosuppresion in spite of reducing lymphocyte counts, of inhibition of T cell proliferation, and/or of reduction of IL-2 production.
In spite of the prolonged survival time of most transfer colitis mice, the aCD2 mAb did not prevent colitis in all mice, and its clinical efficacy in established colitis is limited. In addition, all SCID mice that received CD45RB high T helper cells eventually developed colitis when looking at a later time point. This finding supports previous transplantation studies suggesting that this aCD2 mAb prolongs allogenic heart transplantion. 25 However, tolerance induction can only be achieved upon combination with aCD3, CTLA-4-Ig, or aCD48 mAb. [55] [56] [57] One way of enhancing clinical effectiveness in our study was to add pulse dexamethasone, which did not alter the disease course on its own.
The theoretical benefit of higher doses of aCD2 mAb or shorter injection intervals stands against previous transplantation studies using much lower doses of the same mAb. 25 In conclusion, we have described amelioration or delay of adoptive transfer colitis and attenuation of established colitis by treatment with the aCD2 mAb 12-15. The data demonstrate that a blocking aCD2 mAb can profoundly alter the immune response in a murine model of intestinal inflammation induced by transfer of CD4 þ blasts into immunodeficient RAG1 À/À mice or CD45RB high T cells into SCID mice probably by inhibiting proliferation and decreasing IL-2 production. Still, aCD2 mAb does not impair parasite control in a Toxoplasmosis model. Future studies have to investigate how a CD2 directed immunotherapy can be optimized in IBD animal models and how these findings can be applied to clinical CD2-directed immunotherapies.
